Mass Medical Angels
Anh Ngo is a highly accomplished professional in the fields of venture capital and healthcare innovation, currently serving as a Venture Partner at NextGen Venture Partners since 2019. Concurrently, Anh holds memberships at Mass Medical Angels and the International Neuromodulation Society, and contributes to the Neuromodulation Journal as a peer review board member. With extensive experience at Ideaing as an investor and executive, and as an editorial member for Blockchain in Healthcare Today, Anh combines expertise in smart technology and blockchain applications in healthcare. Prior roles include co-coordinator for Healthcare Innovation & Commercialization at Harvard Medical School, investment fellow at Ascentia Asset Management, and ceo co-founder of Irvine Capital. Anh's medical background includes serving as an anesthesiologist at Beth Israel Deaconess Medical Center and partnership in a large medical practice management company. Educational qualifications comprise advanced degrees in medicine and business from prestigious institutions, including Harvard Medical School and UC Irvine.
This person is not in any teams
Mass Medical Angels
Mass Medical Angels (MA2) was founded to answer the need for a dedicated life-science centric angel group in New England. The Boston area is a world-leading supercluster for medical innovation, but all early-stage companies in the field have tremendous difficulty with first round funding. Our goal is to provide money and mentoring to the life science community to achieve superior returns for our group, and more clinical innovation for the community. Our focus is on early stage life science companies looking to raise $250K to $3.0M. Depending on the amount of funding needed, we can fund all or a portion of the round, and will work closely with other angel groups or venture funds in the area to complete the round. We are looking for companies that are extremely capital efficient opportunities where our funds will lead to significant step-ups in valuation to avoid unfavorable future funding rounds.